Jazz Pharmaceuticals plc Market Cap ($11.86 Billion)
Market Cap & Net Worth: Jazz Pharmaceuticals plc (J7Z)
Jazz Pharmaceuticals plc market cap. Jazz Pharmaceuticals plc (F:J7Z) has a market capitalization of $11.86 Billion (€10.14 Billion) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #1910 globally and #409 in its home market, demonstrating a -1.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jazz Pharmaceuticals plc's stock price €185.70 by its total outstanding shares 62742820 (62.74 Million).
Jazz Pharmaceuticals plc Market Cap History (2015–2026)
Jazz Pharmaceuticals plc market cap history from 2015 to 2026. Data shows growth from $9.54 Billion to $13.62 Billion (3.96% CAGR). Check latest Jazz Pharmaceuticals plc stock price today for real-time trading data and today's change.
Jazz Pharmaceuticals plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jazz Pharmaceuticals plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Jazz Pharmaceuticals plc for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.45x
Jazz Pharmaceuticals plc's market cap is 2.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $7.49 Billion | $1.49 Billion | $396.83 Million | 5.03x | 18.86x |
| 2017 | $8.28 Billion | $1.62 Billion | $487.85 Million | 5.12x | 16.98x |
| 2018 | $7.85 Billion | $1.89 Billion | $447.10 Million | 4.15x | 17.55x |
| 2019 | $9.76 Billion | $2.16 Billion | $523.37 Million | 4.51x | 18.64x |
| 2020 | $9.54 Billion | $2.36 Billion | $238.62 Million | 4.03x | 39.96x |
| 2021 | $8.52 Billion | $3.09 Billion | -$329.67 Million | 2.75x | N/A |
| 2022 | $10.82 Billion | $3.66 Billion | -$224.06 Million | 2.96x | N/A |
| 2023 | $8.13 Billion | $3.83 Billion | $414.83 Million | 2.12x | 19.60x |
| 2024 | $8.55 Billion | $4.07 Billion | $560.12 Million | 2.10x | 15.26x |
| 2025 | $10.47 Billion | $4.27 Billion | -$356.15 Million | 2.45x | N/A |
Competitor Companies of J7Z by Market Capitalization
Companies near Jazz Pharmaceuticals plc in the global market cap rankings as of October 31, 2026. See how leveraged is Jazz Pharmaceuticals plc's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Jazz Pharmaceuticals plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Jazz Pharmaceuticals plc (2015–2026)
Market capitalization of Jazz Pharmaceuticals plc from 2015 to today. Between 2015 and today, Jazz Pharmaceuticals plc's market cap moved from $9.54 Billion to $ 13.62 Billion, with a yearly change of 3.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.62 Billion | +30.04% |
| 2025 | €10.47 Billion | +22.52% |
| 2024 | €8.55 Billion | +5.14% |
| 2023 | €8.13 Billion | -24.85% |
| 2022 | €10.82 Billion | +26.99% |
| 2021 | €8.52 Billion | -10.65% |
| 2020 | €9.54 Billion | -2.26% |
| 2019 | €9.76 Billion | +24.30% |
| 2018 | €7.85 Billion | -5.25% |
| 2017 | €8.28 Billion | +10.66% |
| 2016 | €7.49 Billion | -21.55% |
| 2015 | €9.54 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Jazz Pharmaceuticals plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.86 Billion USD |
| MoneyControl | $11.86 Billion USD |
| MarketWatch | $11.86 Billion USD |
| marketcap.company | $11.86 Billion USD |
| Reuters | $11.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more